It has been reported that pancreatic NET patients with retinoblastoma 1 (RB1) deletion and Kirsten rat sarcoma virus (KRAS) mutations exhibited a better treatment effect with platinum-based chemotherapy. Here, RB1 is linked to pancreatic neuroendocrine tumor.